Japan could allegedly provide the self-developed unapproved drug to help treat Ebola.
Reuters reports with reference to Chief Cabinet Secretary
Yoshihide Suga, who briefed journalists at a recent press conference
held August 25, that Japan was ready to cooperate with the World Health Organization (WHO) by offering their solution.
“I am informed that medical professionals
could make a request for T-705 in an emergency even before a decision
by the WHO. In that case, we would like to respond under certain
criteria.”
T-705 is the developmental code for the influenza
drug favipiravir. The developers, a subsidiary of Fujifilm Holdings
Corp., and the U.S. partner MediVector are currently negotiating with
the U.S. Food and Drug Administration on the permission to to expand the
use of favipiravir to fight Ebola.
Fujifilm spokesman Takao Aoki, explaining the
mechanism of drug use, said Ebola and Influenza are same-type viruses
adding that theoretically similar effects can be expected on Ebola, ABC
News reports. According to the official, the effectiveness of T-705 was
confirmed in experiments on mice. The company representative stated
that it has favipiravir stock for more than twenty thousand patients.
Meanwhile the figure of people who died from Ebola outbreak in West Africa is gradually approaching 1500.